Clinical significance of the determination of surfactant proteins A and D in assessing the activity of lung sarcoidosis


Cite item

Full Text

Abstract

The results of a clinical study showing the importance of surfactant proteins A and D in assessing the activity and progression of idiopathic pulmonary fibrosis and chronic lung sarcoidosis are presented. Aim. To study the clinical significance of SP-A, SP-D in assessing the activity of idiopathic pulmonary fibrosis and sarcoidosis. We examined 81 patients with morphologically confirmed diagnoses of idiopathic pulmonary fibrosis (ILF) and sarcoidosis, a control group of 20 healthy individuals. The MSCT of the thoracic organs of the chest was performed, the diffusivity of the lungs was examined, oxygen saturation was determined. In the serum, the surfactant proteins SP-A and SP-D were determined by the enzyme-linked immunosorbent assay. Results. A significant increase in SP-A and SP-D (p<0.05) was observed in patients compared with patients in the control group, a direct correlation was found with signs of activity: SP-A with alveolitis (p<0.05), SP- D with progressive fibrosis (p<0.05), inverse correlation of surfactant proteins with respiratory function indices (p<0.05). Conclusion. Serological parameters of SP-A and SP-D reflect the activity of alveolitis and the progression of pulmonary fibrosis in patients with ILF and sarcoidosis.

About the authors

V D Beketov

Lomonosov Moscow State University

Email: beketov-vladimir@inbox.ru
аспирант каф. внутренних болезней факультета фундаментальной медицины Moscow, Russia

M V Lebedeva

Federal State Autonomous Educational Institution of Higher Education I.M. Sechenov First Moscow State Medical University

Email: marinaamica@mail.ru
к.м.н., доцент каф. внутренних, профессиональных болезней и пульмонологии Moscow, Russia

N A Mukhin

Lomonosov Moscow State University; Federal State Autonomous Educational Institution of Higher Education I.M. Sechenov First Moscow State Medical University

акад. РАН, д.м.н., зав. каф. внутренних болезней факультета фундаментальной медицины МГУ имени М.В. Ломоносова; зав. каф. внутренних, профессиональных болезней и пульмонологии Первого МГМУ им. И.М. Сеченова Минздрава России Moscow, Russia

A G Serova

Federal State Autonomous Educational Institution of Higher Education I.M. Sechenov First Moscow State Medical University

Moscow, Russia

A B Ponomarev

Federal State Autonomous Educational Institution of Higher Education I.M. Sechenov First Moscow State Medical University

к.м.н., доцент каф. патологической анатомии Moscow, Russia

E N Popova

Federal State Autonomous Educational Institution of Higher Education I.M. Sechenov First Moscow State Medical University

д.м.н., проф. каф. внутренних, профессиональных болезней и пульмонологии Moscow, Russia

A Sh Yanakaeva

Federal State Autonomous Educational Institution of Higher Education I.M. Sechenov First Moscow State Medical University

к.м.н., врач-рентгенолог клинического центра Moscow, Russia

V A Solomka

Federal State Autonomous Educational Institution of Higher Education I.M. Sechenov First Moscow State Medical University

клинический ординатор каф.внутренних, профессиональных болезней и пульмонологии Moscow, Russia

A V Kondrashov

Federal State Autonomous Educational Institution of Higher Education I.M. Sechenov First Moscow State Medical University

клинический ординатор каф. внутренних, профессиональных болезней и пульмонологии Moscow, Russia

D V Konovalov

Federal State Autonomous Educational Institution of Higher Education I.M. Sechenov First Moscow State Medical University

врач отд-ния пульмонологии и профпатологии УКБ№3 Moscow, Russia

References

  1. Интерстициальные болезни легких./ Под ред. Н.А. Мухина. М.: Литтерра. 2007; 434 с.
  2. Мухин Н., Корнев Б., Попова Е. и др. Саркоидоз прогрессирующего течения. Врач. 2003; (8): 20-27.
  3. Baugman R.P, Grutters J.C. New treatment strategies for pulmonary sarcoidosis: antimetabolites, biological drugs, and other treatment approaches. Lancet Respir Med. 2015 Oct;3(10):813-22. doi: 10.1016/ S2213-2600(15)00199-X.
  4. Авдеев С.Н. Идиопатический легочный фиброз. Пульмонология. 2015;25(5):600-612. doi: 10.18093/0869-0189-2015-25-5-600-612. / Аvdeev S. N. Idiopathic pulmonary fibrosis. Pulmonology. 2015;25 (5):600-612. doi: 10.18093/0869-0189-2015-25-5-600-612.
  5. Илькович М.М. Интерстициальные заболевания легких: рассуждения на актуальную тему. Часть 2// Consilium Medicum. Болезни органов дыхания. (Прил.). 2014; 01: 7-9.
  6. Мухин H.A., Серов В.В., Коган Е.А. и др. Клинико - морфологическая характеристика интерстициальных болезней легких. Клин медицина. 1995; (3): 77-80.
  7. Raghu G, Lynch D, Godwin J.D et al. Diagnosis of idiopathic pulmonary fibrosis with high - resolution CT in patients with little or no radiological evidence of honeycombing: secondary analysis of a randomised, controlled trial. Lancet Respir Med. 2014 Apr;2(4):277-84. doi: 10.1016/S2213-2600(14)70011-6.
  8. Микеров А.Н. Роль сурфактантного белка А в иммунной защите легких. Фундаментальные исследования. 2012; (2): 204-207.
  9. Greene K.E, King T.E. Jr, Kuroki Y et al. Serum surfactant proteins-A and -D as biomarkers in idiopathic pulmonary fibrosis. Eur Respir J. 2002 Mar;19(3):439-46.
  10. Ishikawa T, Kubota T, Abe H et al. Surfactant protein-D is more useful than Krebs von den Lungen 6 as a marker for the early diagnosis of interstitial pneumonitis during pegylated interferon treatment for chronic hepatitis C. Hepatogastroenterology. 2012 Oct;59(119):2260-3. doi: 10.5754/hge10868
  11. Nakamura K, Kato M, Shukuya T et al. Surfactant protein-D predicts prognosis of interstitial lung disease induced by anticancer agents in advanced lung cancer: a case control study. BMC Cancer. 2017 May 2;17(1):302. doi: 10.1186/s12885-017-3285-6.
  12. Чучалин А.Г., Визель А.А., Илькович М.М. и др. Диагностика и лечение саркоидоза: резюме федеральных согласительных клинических рекомендаций (Часть II. Диагностика, лечение, прогноз). Вестник современной клинической медицины. 2014; 7 (выпуск 5): 73-81.
  13. Идиопатический легочный фиброз. Клинические рекомендации Минздрава РФ, 2016: 44 c.
  14. Launois C, Barbe C, Bertin E et al. The modified Medical Research Council scale for the assessment of dyspnea in daily living in obesity: a pilot study BMC Pulmonary Medicine. 2012; 12:61. doi: 10.1186/ 1471-2466-12-61.
  15. Программа «STATISTICA Advanced”. Описание. http://statsoft.ru/ products/STATISTICA_Advanced/ актуально на 25.07.2017.
  16. Сергиенко В.И., Бондарева И.Б. Математическая статистика в клинических исследованиях. Практическое руководство. М.: ГЭОТАР- Медиа, 2006; 304.
  17. Chernecky C.C. Laboratory tests and diagnostic procedures / C.C. Chernecky, B.J. Berger; 5th ed. - Saunder Elsevier, 2008. - 1232 pp.
  18. Hara Y, Shinkai M, Kanoh S et al. Arterial Carboxyhemoglobin Measurement Is Useful for Evaluating Pulmonary Inflammation in Subjects with Interstitial Lung Disease. Intern Med. 2017;56(6):621-626. doi: 10.2169/internalmedicine.56.7418.
  19. Лапин С.В., Тотолян А.А. Иммунологическая лабораторная диагностика аутоиммунных заболеваний. СПб.: Человек, 2010. - с. 272.
  20. Волель Б., Макух Е., Лебедева М. и др. Клинико - лабораторные маркеры астенического синдрома у больных саркоидозом. Врач. 2016;( 7): 74-76.
  21. Spagnolo P, Sverzellati N, Rossi G. IPF in 2016: towards a better diagnosis. Lancet Respir Med. 2016 Dec;4(12):945-947. doi: 10.1016/ S2213-2600(16)30375-7.
  22. King C.S, Nathan S.D. Idiopathic pulmonary fibrosis: effects and optimal management of comorbidities. Lancet Respir Med. 2017 Jan;5 (1):72-84. doi: 10.1016/S2213-2600(16)30222-3.
  23. Raghu G, Richeldi L. Current approaches to the management of idiopathic pulmonary fibrosis. Respir Med. 2017 Aug;129:24-30. doi: 10.1016/j.rmed.2017.05.017.

Copyright (c) 2018 Consilium Medicum

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
 
 


This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies